Background: Nicotinic acetylcholine receptors (nAChRs) are involved in nicotine addiction and some neurological disorders. Results: A novel positive allosteric modulator potentiates activation through the C-tail of one ␣4 subunit but requires two ␣4 to reactivate desensitized nAChRs. Conclusion: Higher occupancy in allosteric sites promotes nAChR opening and alleviates desensitization. Significance: These ␣4 modulators may be useful for basic and clinical applications.
Positive allosteric modulators (PAMs) of nicotinic acetylcholine receptors (nAChR) are important therapeutic candidates as well as valuable research tools. We identified a novel type II PAM, (R)-7-bromo-N-(piperidin-3-yl)benzo[b]thiophene-2carboxamide (Br-PBTC), which both increases activation and reactivates desensitized nAChRs. This compound increases ace-
tylcholine-evoked responses of ␣2* and ␣4* nAChRs but is without effect on ␣3* or ␣6* nAChRs (* indicates the presence of other nAChR subunits). Br-BPTC acts from the C-terminal extracellular sequences of ␣4 subunits, which is also a PAM site for steroid hormone estrogens such as 17␤-estradiol. Br-PBTC is much more potent than estrogens. Like 17␤-estradiol, the non-steroid Br-PBTC only requires one ␣4 subunit to potentiate nAChR function, and its potentiation is stronger with more ␣4 subunits. This feature enables Br-BPTC to potentiate activation of (␣4␤2)(␣6␤2)␤3 but not (␣6␤2) 2 ␤3 nAChRs. Therefore, this compound is potentially useful in vivo for determining functions of different ␣6* nAChR subtypes. Besides activation, Br-BPTC affects desensitization of nAChRs induced by sustained exposure to agonists. After minutes of exposure to agonists, Br-PBTC reactivated short term desensitized nAChRs that have at least two ␣4 subunits but not those with only one. Three ␣4 subunits were required for Br-BPTC to reactivate long term desensitized nAChRs. These data suggest that higher PAM occupancy promotes channel opening more efficiently and overcomes short and long term desensitization. This C-terminal extracellular domain could be a target for developing subtype or state-selective drugs for nAChRs.
Nicotinic acetylcholine receptors (nAChRs) 2 are critical for nicotine addiction and important for several neuropsychiatric disorders (1) (2) (3) . They are ligand-gated ion channels formed from five homologous subunits whose subtypes are defined by their subunit composition. There are 12 neuronal types of subunits: ␣2-10 and ␤2-4. Homomeric nAChRs like ␣7 assemble from only ␣7 subunits, whereas heteromeric nAChRs usually require both ␣ and ␤ subunits (4, 5) . Both homomeric and heteromeric nAChRs form orthosteric agonist binding sites at interfaces between the subunits in the extracellular domain. Recently, various ligands have been identified that activate, inhibit, or potentiate activation of nAChRs from allosteric sites other than the agonist binding sites (4, 6, 7) . These include positive allosteric modulators (PAMs), negative allosteric modulators, and allosteric agonists (6, 8, 9) . These drugs bind to various places in nAChRs, including the extracellular domain, transmembrane domain, and the extracellular C terminus (e.g. C-tail) (6, 7) . There are interests in developing PAMs because agonists both activate and desensitize nAChRs and because subtype selectivity is hard to achieve with agonists due to similarity between ACh binding in different nAChR subtypes. By contrast, PAMs enhance nAChR function in an activity-dependent manner, potentially modulating the endogenous pattern of signaling rather than constantly activating or desensitizing nAChRs. PAMs also increase the potential for subtype specificity. This is because diversity of PAM binding sites in nAChRs provides better chances to develop selective therapeutics than does targeting the relatively similar ACh binding sites.
Based on pharmacology, there are two types of PAMs (10) . Type I PAMs increase peak responses. Type II PAMs not only increase peak responses but also the duration of channel opening by delaying desensitization. This makes type II PAMs espe-* This work was supported by National Institute on Drug Abuse Grant DA030929. The authors declare that they have no conflicts of interest with the contents of this article. 1 cially efficacious. In some cases they can act as allosteric agonists (8) . Understanding the pharmacology and potentiation mechanism of PAMs should facilitate design of more potent and selective modulators. There is no direct correlation between where a PAM binds and which type of PAM it is (6) . Some PAMs bind in the transmembrane domain near the gate for the cation channel whose opening they influence (6) . These transmembrane PAMs can be either type I or type II. Here we describe a novel type II PAM, Br-PBTC, 3 which acts from the C-tail of the ␣4 subunit. Discovering how this site, which is distant from both agonist binding sites and the channel gate, influences activation and desensitization should provide new insights on the structure and function of nAChRs.
Higher occupancy of agonist sites increases activation and speed of desensitization of both heteromeric and homomeric nAChRs (11) (12) (13) . Knowledge of how binding of PAMs affects activation and desensitization is limited. Some estrogens act as PAMs through the C-tail of ␣4 (14) . Their PAM effect increases with the number of ␣4 subunits with free C-tails in a nAChR (15) . By contrast, Br-PBTC potentiates ␣4 concatemers and free ␣4 subunits. Using this novel PAM and various concatemers, we investigated how PAM site occupancy influences activation and desensitization of nAChRs expressed in Xenopus oocytes and mammalian cell lines. We found that occupying one PAM site is sufficient to potentiate nAChR activation, and higher PAM site occupancy promotes nAChR opening and alleviates short and long term desensitization more efficiently. This C-tail potentiation mechanism might be applicable to other nAChR subtypes and facilitate development of other subtypeselective drugs.
Experimental Procedures
Chemicals-Methodology for preparing reactants for synthesizing Br-PBTC is described as follows.
Ethyl 7-Bromobenzo[b]thiophene-2-carboxylate-3-Bromo-2-fluorobenzaldehyde (406.0 mg, 2.0 mmol), ethyl mercaptoacetate (242 l, 2.2 mmol), triethylamine (556 l, 4.0 mmol), and acetonitrile (10 ml) were added to a 50-ml round-bottom flask and stirred at 60°C overnight. The acetonitrile was removed in vacuo, and the residue was dissolved in ethyl acetate (30 ml) and water (10 ml). The layers were separated, and the aqueous layer was extracted with ethyl acetate (2ϫ). The combined organics were dried (MgSO 4 ) and concentrated to give the title compound (538 mg, 95%). 1 (6 ml) , and water (8 ml) were added to a 50-ml round-bottom flask and stirred at room temperature until the starting material was consumed as judged by thin layer chromatography analysis. The majority of the tetrahydrofuran was removed in vacuo. The resulting crude mixture was acidified with aqueous hydrochlo-ric acid (ϳpH ϭ 3) and cooled in an ice bath. The solids were filtered and washed with cold water (about 6 ml) to give the title compound (392 mg, 90%).
Synthesis of Br-PBTC-A mixture of 7-bromobenzo[b]thiophene-2-carboxylic acid (25.6 mg, 0.1 mmol), (R)-tert-butyl 3-aminopiperidine-1-carboxylate (24.0 mg, 0.12 mmol), N,Ndiisopropylethylamine (52 l, 0.3 mmol), and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (57.0 mg, 0.15 mmol) in dimethylformamide (2 ml) was stirred at room temperature for 12 h. The reaction mixture was diluted with ethyl acetate (15 ml) and washed with water (4 ml, 3ϫ). The organic layer was dried (MgSO 4 ) and concentrated in vacuo. The crude residue was dissolved in CH 2 Cl 2 (5 ml), trifluoroacetic acid (TFA) (5 ml) was added, and the reaction was stirred at room temperature for 1 h. The reaction was concentrated in vacuo to give a crude product, which was purified by reverse-phase preparative HPLC (A: methanol and acetonitrile (1:1, v/v); B: water containing TFA (0.1%, v/v)). The title compound was obtained as the TFA salt (31.6 mg, 70%). 1 cDNAs and cRNAs-Human ␣2, ␣3, ␣4, ␣6, ␤2, and ␤4 were cloned in this laboratory (13, 16 -19) . Concatemers were formed by linking the C terminus of one subunit to the N terminus of the next. The trimeric concatemer ␤2(QAP) n ␣4(QAP) n ␤2 (abbreviated as ␤2-␣4-␤2) was synthesized through linking together ␤2(QAP) n ␣4 with QAP linker and ␤2. ␤2(QAP) n ␣4 was made similarly as ␤3(QAP) n ␣6, which was described (20) . A BspEI site was introduced at the end of the mature peptide of ␤2 using a CCCAGCTC-CAAGTCCGGACCTTCCTCATCTC oligonucleotide. The (QAP) n linker was then inserted between the BspEI site at the end of ␤2 and the FspI site at the beginning of ␣4. At the end of the coding domain of ␣4 in the ␤2QAP␣4 dimer we introduced a AgeI site (GCTGGCTGGCATGATCACCGGTGGGAC-CGGGAGCCTG oligonucleotide), which is complementary to the XmaI site of the second (QAP) n linker in the concatemer ␤2(QAP) n ␣4(QAP) n ␤2. The second (QAP) n linker was prepared from the ␤2(QAP) n ␣4 piece. We mutated the FspI site at the beginning of the ␣4 sequence into a BstBI site. The second (QAP) n linker with new restriction sites was cut out using XmaI site and BstBI enzymes. We introduced a BstBI restriction site at the beginning of the mature peptide of ␤2 using a GGCAT-GATCTTCGAAACGGATACAGAGGAG oligonucleotide. These allowed us to link together the ␤2QAP␣4 dimer with the AgeI site, the QAP linker with XmaI and BstBI ends, and the ␤2 subunits with the BstBI restriction site at the beginning of mature peptide. The resulting construct was recloned into the pBS SK(Ϫ) vector using the EcoRI restriction enzyme. The resulting clone linearized with EcoRV for expression in oocytes. Syntheses of tetrameric and pentameric concatemers (i.e. ␤2-␣4-␤2-␣4 and ␤3-␣6-␤2-␣4-␤2) was described (21, 22) .
Four of the five chimeras of ␣3 and ␣4 subunits were prepared previously (23) . Chimeras were numbered according to the amino acid sequences of the mature subunit. ␣3 (1-440) / ␣4 (561-594) was prepared by ligating three pieces of DNA: a 0.6-kb fragment from the NcoI to BstEII site of the ␣3 subunit, a 1-kb fragment from the HidIII to BstEII site of the ␣3 subunit, and a 3.1-kb fragment from the NcoI to HidIII site of the ␣4 subunit in the pSP64 vector. The ligation mixture was transformed into XL10-Gold ultracompetent cells (Stratagene, La Jolla, CA), and the right clone was chosen from a restriction enzyme digest.
A C-tail mutant (noted as ␣4 AAC ) was obtained by mutating the last four amino acids of the ␣4 subunit, alanine-glycinemethionine-isoleucine, to alanine-alanine-cysteine followed by a stop codon. Mutations were introduced using the PfuUltra high-fidelity DNA polymerase (Agilent, Santa Clara, CA) following the manufacturer's instructions. All mutations were confirmed by sequencing.
After linearization and purification of cDNAs, cRNA transcripts were prepared in vitro using mMessage mMachine kits (Ambion, Austin, TX). Concentrations of cDNAs and cRNAs were calculated by spectrophotometry.
Cell Culture and Transfection-All cells were maintained as described previously (17) . The human embryonic kidney tsA201 (HEK) cell lines stably expressing human ␣4␤2, ␣4␤4, ␣2␤2, ␣2␤4, ␣3␤2, and ␣3␤4 were described (13) . The ␣4␤2 cell line expresses a mixture of (␣4␤2) 2 ␣4 and (␣4␤2) 2 ␤2 nAChRs (24) . HEK cells that express only one stoichiometry, either (␣4␤2) 2 ␣4 or (␣4␤2) 2 ␤2, were obtained by transfecting a dimeric concatemer ␤2(QAP) n ␣4 cell line with ␣4 or ␤2 subunits. 4 FLEXstation Experiments-For functional tests of nAChRs expressed in HEK cells, we used a FLEXstation (Molecular Devices, Sunnyvale, CA) bench-top scanning fluorometer as described by Kuryatov et al. (25) . To increase the expression level of ␣2␤3, ␣3␤2, and (␣4␤2) 2 ␤2 nAChRs, the plates were incubated at 29°C for 20 h before being tested. A membrane potential fluorescent indicator kit (Molecular Devices) was used according to the manufacturer's protocols. In PAM experiments, serial dilutions of Br-PBTC were manually added to the assay plate 15 min before the addition of agonists during recording unless otherwise noted. In short term desensitization experiments, 6 min after agonists were added to cell culture wells, Br-PBTC or dihydro-␤-erythroidine hydrobromide (DH␤E) was automatically added into the wells during recording. In long term desensitization experiments, nicotine or DH␤E was incubated with cells for 6 h before recording. Br-PBTC with or without DH␤E was added to the cell culture wells during recording. Each data point was averaged from three to four responses from separate wells. The potency and maximum efficacy of drugs were calculated by fitting the Hill equation to the concentration/response relationship using a nonlinear least squares curve fitting method (Kaleidagraph; Abelbeck/Synergy, Reading, PA):
n H )], where I(x) is the peak current measured at the drug concentration x, I max is the maximum current peak at the saturating concentration, EC 50 is the drug concentration required to achieve half of the maximum response, and n H is the Hill coefficient.
Ooctye Removal and Injection-Oocytes were removed surgically from Xenopus laevis and defolliculated as described (13, 18) .
Oocyte injections were performed within 48 h after surgery. Oocytes were injected with 20 -40 ng of concatemer cRNA and free single subunit at a 1:1 ratio. A total of 2-20 ng of cRNA was injected for free wild type or chimeric ␣ and ␤ subunits at a 4:1 ratio to force expression of the (␣) 3 (␤2) 2 stoichiometry or at 1:4 ratio to force expression of the (␣) 2 (␤) 3 stoichiometry. To express homomeric ␣7 nAChRs, 70 ng of cRNA was injected to each oocyte. The function was assayed 3-7 days after injection.
Electrophysiology-Currents in oocytes were measured using the OpusXpress 6000A (Molecular Devices, Union City, CA), an automated two-electrode voltage clamp amplifier that enables recording up to eight oocytes in parallel (13) . Oocytes were voltage-clamped at a holding potential of Ϫ50 mV. 200 l of drugs were delivered on top of oocytes for 4 s (s) through the sidewall of the bath to minimize disturbance to oocytes. Between drug applications, oocytes received a 30-s prewash and 223-s post-wash of ND96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, pH 7.6) with 0.5 M atropine perfused through the bath at a rate of 3 ml/min unless otherwise noted.
Peak amplitudes of experimental responses were calculated relative to ACh responses to normalize the data and compensate for variable expression levels among oocytes. The PAM effect of Br-PBTC was calculated by comparing increased responses with Br-PBTC relative to responses to ACh alone. Mean and S.E. were calculated from normalized responses. Statistical analyses were performed using Student's t test. More than four oocytes were tested for each experiment.
Pre-application of Br-PBTC gave slightly higher PAM effects on wild type and chimeric nAChRs than co-application with agonists. But conclusions were the same for both application methods. To save time, we thereafter used the co-application method to evaluate the PAM effects in experiments performed in oocytes. In short term desensitization experiments, 1 mM ACh was applied to oocytes for 4 s at the rate of 3 ml/min followed by another 56 s at 0.75 ml/min. Then the oocytes were incubated for an additional 5 min in a static bath before a coapplication with 1 mM ACh plus 3 M Br-PBTC for 4 s at 3 ml/min. Control experiments were performed on the same oocytes before Br-PBTC applications following the same protocol in which 3 M Br-PBTC was replaced with 0.1% (v/v) DMSO. Reactivation by Br-PBTC was calculated by normalizing the response of 3 M Br-PBTC to the response of ACh applied before Br-PBTC. In antagonist inhibition experiments, ␣-conotoxin MII was applied for 4 s at the rate of 3 ml/min followed by another 56 s at 0.75 ml/min. To fully block ACh activation, the oocytes were then incubated for an additional 16 min in a static bath before co-application of ACh (3 M) or ACh together with Br-PBTC (3 M).
Results
Br-PBTC Selectively Affects ␣2 and ␣4 Subunits-To investigate the subtype selectivity of compound Br-PBTC ( Fig. 1A) , we tested its ability to potentiate ACh activation of various subtypes of nAChRs stably expressed in HEK cells ( Fig. 1B ). Br-PBTC increased the activation by EC 20 ACh of ␣2and ␣4-containing nAChRs by 119 -560% (Table 1) . EC 50 values for Br-PBTC ranged from 0.261 to 0.660 M (Table 1) , equal to the most potent nAChR PAMs (6, 7) . At Ͼ3 M, Br-PBTC inhibited its own potentiation effect, perhaps because it behaved as an open channel blocker like some other nAChR PAMs and ACh itself (26) . Br-PBTC did not alter activation by ACh of ␣3␤2 or ␣3␤4 nAChRs ( Fig. 1B) . We also evaluated the effect of Br-PBTC (up to 3 M) on activation on homomeric ␣7 nAChRs expressed in Xenopus oocytes. The maximum increased peak response by Br-PBTC was 33.9 Ϯ 33.8%. Because the potentiation is small with large error and only appeared at 1 M Br-PBTC, we do not think that Br-PBTC potentiates activation of ␣7 nAChRs. Br-PBTC did not activate these heteromeric or homomeric nAChR subtypes by itself (data not shown). Therefore, Br-PBTC is an ␣2 and ␣4 nAChR subtype-selective PAM.
Br-PBTC potentiated activation of ␤2-containing nAChRs more than ␤4-containing nAChRs. The relatively higher efficacy of Br-PBTC on ␣2␤2 and ␣4␤2 nAChRs could result from Br-PBTC having greater effects on the (␣␤) 2 ␣ stoichiometry or from the preference of Br-PBTC for ␤2 over ␤4. Our ␣4␤4 nAChR cell line expresses both (␣4␤4) 2 ␤4 and (␣4␤4) 2 ␣4 stoichiometries (13) . To express fixed stoichiometries of ␣4␤2 and ␣4␤4, we transiently overexpressed one subunit over the other in oocytes. We used 3 M Br-PBTC to study its potentiation effects on activation of (␣4␤2) 2 ␣4, (␣4␤2) 2 ␤2, (␣4␤4) 2 ␣4, and (␣4␤4) 2 ␤4 by various concentrations of ACh (Fig. 2 ). Br-PBTC has a greater effect on ␤2* than ␤4* nAChRs with the same stoichiometry. It increased maximum ACh efficacy of the (␣4␤2) 2 ␣4 by 6.8 Ϯ 2.2-fold, larger than the 1.7 Ϯ 0.1-fold increase on (␣4␤4) 2 ␣4 nAChRs. Br-BPTC increased activation of (␣4␤2) 2 ␤2 but showed no effect on (␣4␤4) 2 ␤4. However, Br-PBTC did potentiate the activation of the (␣2␤4) 2 ␤4 stoichiometry as evidenced by its action on our ␣2␤4 cell line, which only expresses this stoichiometry (13) . Therefore, Br-PBTC potentiates activation of both (␣␤) 2 ␣ and (␣␤) 2 ␤ stoichiometries but has a weaker effect on ␤4-containing than ␤2-containing nAChRs.
Br-PBTC increased the maximum ACh efficacy of the two stoichiometries of ␣4␤2 greatly in oocytes ( Fig. 2 ). We investigated whether Br-PBTC potentiates activation of nAChRs with defined stoichiometries expressed in HEK cell lines. The defined stoichiometries were obtained by expressing a ␤2-␣4 concatemer with a free ␣4 or ␤2 subunit (Fig. 3A) . These cell lines also allowed us to study the effect of Br-PBTC on long term desensitized nAChRs, which is described in later sections. Br-PBTC enhanced activation by EC 40 -50 ACh of both stoichiometries. It is 2.5-fold more efficacious at activation of the (␣4␤2) 2 ␣4 stoichiometry by EC 40 -50 ACh (Fig. 3A) . But its potentiation efficacies evaluated by ACh at EC 100 are similar between the two stoichiometries ( Fig. 3, B and C) . The potencies of Br-PBTC are similar for the two stoichiometries, at ϳ200 nM (Table 1 ). (␣4␤2) 2 ␤2 nAChRs have two high ACh sensitivity sites each at ␣4/␤2 interfaces. (␣4␤2) 2 ␣4 nAChRs have these two high sensitivity sites and a third low ACh sensitivity site at the ␣4/␣4 interface (27, 28) . The different potentiation effects evaluated by medium and maximal concentrations of ACh could result from different effects of Br-PBTC on sensitivity of nAChRs. The ACh concentration/response curve of (␣4␤2) 2 ␣4 nAChRs in the absence of Br-PBTC contains two components representing the high affinity ␣4/␤2 agonist sites (EC 50 1 ϭ 0.220 Ϯ 0.056 M) and the low affinity ␣4/␣4 site (EC 50 2 ϭ 18.1 Ϯ 5.7 M) in this nAChR subtype. In the pres- ence of Br-PBTC, the ACh concentration/response curve became monophasic with EC 50 ϭ 0.0481 Ϯ 0.0043 M ( Fig. 3B and Table 2 ). Therefore, Br-PBTC has a much higher effect on activation of (␣4␤2) 2 ␣4 nAChRs by EC 40 -50 ACh than by EC 100 ACh. Conversely, Br-PBTC had little effect on the potency of (␣4␤2) 2 ␤2 nAChRs, EC 50 (without Br-PBTC) ϭ 0.992 Ϯ 0.193 M, and EC 50 (with Br-PBTC) ϭ 0.429 Ϯ 0.079 M (Table 2) . Therefore, Br-PBTC has a lower efficacy on activation of (␣4␤2)2␤2 than (␣4␤2)2␣4 nAChRs when evaluated by EC 40 -50 ACh. Two effects might account for the difference of potency changes by Br-PBTC on the two stoichiometries; 1) Br-PBTC requires the three ␣4 subunits to affect agonist affinity, or 2) Br-PBTC increases agonist affinity to the low ACh affinity ␣/␣ site but does not affect the high ACh affinity ␣/␤ sites. To test these hypotheses, we expressed ␤2-␣4-␤2-␣4 concatemers with ␣3 subunits in oocytes to obtain (␣4␤2) 2 ␣3, which has two ␣4␤2 binding sites like (␣4␤2) 2 ␤2 and an additional low ACh affinity ␣3␣4 site very similar to the ␣4/␣4 agonist site (13) . In parallel, we also expressed (␣4␤2) 2 ␣4 and (␣4␤2) 2 ␤2 in oocytes. The Br-PBTC potentiation effects on ACh efficacy were greater in oocytes than in HEK cells ( Table 2 ). This could be because the Br-PBTC potentiated activation by the high concentration of ACh reached the detection limit of the membrane potential dye that is used to assay HEK cells or because the different lipid environment between HEK cells and oocyte affected conformational change induced by Br-PBTC. However, Br-PBTC potentiation effects on ACh potencies of (␣4␤2) 2 ␣4 and (␣4␤2) 2 ␤2 were similar on oocytes and HEK cells. Br-PBTC increased the sensitivity of (␣4␤2) 2 ␣4 to ACh by 37-fold but had a minimal effect on the sensitivities of (␣4␤2) 2 ␣3 and (␣4␤2) 2 ␤2 (Table 2 ). This suggests that three ␣4 subunits are required for Br-PBTC to increase agonist sensitivity of nAChRs.
In summary, Br-PBTC is an ␣2/␣4 subtype-selective PAM. It increases potencies of nAChRs with three ␣4 subunits and efficacies of nAChRs with two or three ␣4 subunits. Its potentiation effect is larger on ␤2-containing than ␤4-containing nAChRs. The following pharmacology study mainly focused on ␣4␤2* nAChRs, which are the most prevalent nAChRs in brain.
Br-PBTC Potentiates Activation from the Extracellular C-terminal Domain of ␣4 Subunits-Because Br-PBTC has no effect on ␣3* nAChRs, we expressed various chimeras of ␣3 and ␣4 subunits in Xenopus oocytes to identify the Br-PBTC potentiation site in the ␣4 subunit. Fig. 4 illustrates the chimeras of ␣3 and ␣4 used. Because Br-PBTC potentiates activation of ACh more strongly at intermediate agonist concentrations, we used ACh at EC 30 -40 to test the PAM effects of Br-PBTC on ␣3␤2, ␣4␤2, and their chimeras (Fig. 5A ). Br-PBTC could not activate nAChRs by itself but increased ACh activation of ␣4␤2 nAChRs expressed in oocytes by 385 Ϯ 61% (Fig. 5 ). Similar to the HEK cell results, Br-BPTC did not potentiate ␣3␤2 nAChRs expressed in oocytes. Chimeras ␣4 (1-207) /␣3 (208 -446) and ␣4 (1-297) /␣3 (298 -446) , which have the ␣3 cytoplasmic, M4, and C-tails, abolished potentiation by Br-PBTC. Chimeras retaining ␣4 sequences in these domains, ␣3 (1-207) /␣4 (208 -594) and ␣3 (1-297) /␣4 (298 -594) , exhibited Br-PBTC potentiation. In the chimera ␣3 (1-440) /␣4 (561-594) , Br-PBTC PAM effects resembled wild type ␣4 subunit (Fig. 5 ). These data suggest that Br-PBTC potentiates from the region M4 to the C terminus and is likely to bind in or close to this region. The C-tail of human ␣4 binds to endogenous steroids such as 17␤-estradiol (14, 29) . To test whether Br-PBTC binds to the ␣4 subunit C-tail, we mutated the last four amino acids of human ␣4 subunit (AGMI) to alanine-alanine-cysteine, noted as ␣4 AAC . This AAC sequence corresponds to the C-tail of the rat ␣4 subunit and when substituted for the last four amino acids of human ␣4 abolished potentiation by 17␤-estradiol (14) . This mutant decreased potentiation by Br-PBTC to 70 Ϯ 18% (p Ͻ 0.01 compared with wild type; Fig. 5 ). Attenuation instead of elimination of the Br-PBTC PAM effect by this C-tail mutant suggests that Br-PBTC binds to the C-tail but closer to the M4 domain than does 17␤-estradiol. Both the AAC mutation and an additional tryptophan to leucine mutation before the AGMI sequence are required to abolish potentiation by an ethynyl derivative of 17␤-estradiol (14) . This tryptophan may help retain the PAM effect of Br-BPTC via cationinteraction between the tryptophan side chain and the secondary amine of Br-PBTC.
Br-PBTC Potentiates nAChRs through a Single ␣4 Subunit-PAM efficacy of 17␤-estradiol increases with more free ␣4 C-tails in a nAChR (15) . Because Br-PBTC also binds to this C-tail site, we investigated the effect of the number of ␣4 subunits on the potentiation profile of Br-PBTC. Br-PBTC does not affect functions of ␣3* nAChRs; thus, we expressed the free ␣3 subunit with various concatemers of ␣4 and ␤2 subunits in Xenopus oocytes to decrease the numbers of Br-PBTC potentiation sites in a nAChR (Fig. 6A ). Another benefit of using ␣3 to replace the ␣4 subunit is that then these nAChRs have the same numbers of agonist binding sites. They all have at least one high ACh affinity ␣4/␤2 site. A low affinity ACh site can be formed at ␣4/␣4 and ␣3/␣4 interfaces (13, 27, 28). (␣3␤4) 2 ␣3 nAChRs showed lower ACh sensitivity than (␣3␤4) 2 ␣4 nAChRs (30). Therefore, a low affinity ACh site is likely to be present at the ␣3/␣3 interface.
We tested the effect of 3 M Br-PBTC on peak currents evoked by ACh, a feature shared by both type I and type II PAMs (Fig. 6B ). This concentration is enough to evoke a max- 
TABLE 2 Effect of 3 M Br-PBTC on potencies and efficacies of ACh to activate nAChRs
ACh concentration/response curves were determined on oocytes or HEK cell lines expressing defined stoichiometries. The maximum efficacy was defined as 100% for ACh without PAMs. In oocytes, defined stoichiometries were obtained by injecting ␤2-␣4-␤2-␣4 concatemers with a free subunit. Each data point was collected from more than four oocytes or more than three wells of cells. The (␣4␤2) 2 ␣4 cell line exhibits a two-component concentration/response curve due to a high sensitivity component reflecting its two ␣4/␤2 ACh binding sites and a low affinity component reflecting activation in combination with the low sensitivity ␣4/␣4 site. The concentration/response data for (␣4␤2) 2 ␣4 obtained from oocytes were too noisy to fit a biphasic curve, so were approximated with a monophasic curve. Allosteric Potentiation from ␣4 C-tail NOVEMBER 27, 2015 • VOLUME 290 • NUMBER 48
imal PAM effect for nAChRs containing two or three ␣4 subunits (Fig. 3A) . Br-PBTC potentiated activation of (␣4␤2) 2 ␣4 nAChRs expressed from the ␤2-␣4-␤2-␣4 concatemer and free ␣4 similarly to those expressed from only free subunits ( Figs. 5A  and 6 ). This is different from estrogens, which do not potentiate concatemers in which the ␣4 subunit C-tail is linked to another subunit such as ␣4-␤2 (29, 31) . Therefore, the concatemer linker has no effect on potentiation by Br-PBTC. Br-PBTC increased activation of nAChRs by both medium (100 M) and maximal (3000 M) concentrations of ACh as long as there was more than one ␣4 subunit (Fig. 6B ). This is consistent with the property of 17-␤ estradiol, another known C-tail binding PAM (15) . Moreover, the potentiation effect of (␣4␤2) 2 ␣3 nAChRs with two ␣4 subunits was larger, and the effect on (␣4␤2) 2 ␣4 with three ␣4 subunits was the largest. These data suggest that higher PAM occupancy increases the efficiency of channel opening. Br-PBTC can increase channel activation by a maximal concentration of ACh. This is similar to what was observed with ␣4␤2 nAChRs expressed in HEK cells (Fig. 3B) . At higher concentrations of agonists, nAChRs desensitize more rapidly. The potentiation by Br-PBTC on 3000 M ACh could be due to increasing channel conductance or increased open state probability or destabilizing or slowing entry into the desensitized state.
Br-PBTC Can Reactivate Both Short Term and Long Term Desensitized nAChRs-To investigate whether Br-PBTC affects channel desensitization, we applied 1000 M ACh for 6 min to oocytes expressing ␣4* nAChRs to desensitize nAChRs before acute application of Br-PBTC (3 M) with ACh (1000 M) (Fig.  7) . Representative response kinetics are shown in Fig. 7B . Most of the nAChRs were desensitized after 6 min of incubation with ACh. Br-PBTC reactivated both (␣4␤2) 2 ␣4 and (␣4␤2) 2 ␣3, but it had little effect on (␣4␤2)(␣3␤2)␣3 nAChRs. This suggests that this type II effect requires binding to two or more ␣4 subunits. This type II property of Br-PBTC was also observed in mammalian HEK cells that express (␣4␤2) 2 ␣4 or (␣4␤2) 2 ␤2 nAChRs (Fig. 8) . Br-PBTC reactivated nAChRs desensitized by either ACh or nicotine for 6 min. We use a membrane potential fluorescent indicator to assay nAChR responses in HEK cells.
This method is not as sensitive to the kinetics of channel function as the two-electrode voltage clamp method performed on oocytes. Therefore, we did not observe a higher PAM effect on desensitized (␣4␤2) 2 ␣4 than (␣4␤2) 2 ␤2 (Fig. 8) , as we expected from oocyte experiments (Fig. 7) . Another factor contributing to this discrepancy is that because (␣4␤2) 2 ␤2 desensitizes slower than (␣4␤2) 2 ␣4, more (␣4␤2) 2 ␤2 nAChRs were still in the open state (represented by the portion blocked by DH␤E applied alone in Fig. 8 ) when Br-PBTC was applied. This was not the case for the experiments we performed on ␣4* nAChRs expressed in oocytes (Fig. 7) .
Unlike ACh, which is quickly hydrolyzed by esterase, nicotine can persist in brains for hours (32) . This causes long term desensitization of nAChRs in smokers. Because Br-PBTC can reactivate short term desensitized nAChRs with more than two ␣4 subunits ( Figs. 7 and 8) , we studied its effect on nAChRs expressed in HEK cells after 6 h of exposure to 0.5 M nicotine (Fig. 9 ). This concentration of nicotine is found in smokers (32) . After 6 h with nicotine, nAChRs were all desensitized because application of DH␤E to these nAChRs showed no blockage of activation (black traces in Fig. 9, A and B) . Interestingly, Br-PBTC (4 M) efficiently reactivated nicotine long term desensitized (␣4␤2) 2 ␣4 nAChRs but only weakly reactivated desensitized (␣4␤2) 2 ␤2 nAChRs (Fig. 9, A and B) . The desensitized (␣4␤2) 2 ␤2 could be less sensitive to reactivation by Br-PBTC. Therefore, we determined the dependence on Br-BPTC concentration of reactivation of desensitized nAChRs (Fig. 9C) . . Br-PBTC reactivates short term desensitized nAChRs expressed in oocytes. To desensitize nAChRs, ACh (1000 M) was applied to oocytes for 6 min before its co-application with Br-PBTC (3 M). Each data point was collected from more than five oocytes. A, Br-PBTC requires two or more ␣4 subunits to reactivate short term desensitized nAChRs. The efficacy of reactivation increases with more ␣4 subunits in a nAChR. B, response kinetics from representative oocytes. Results are the mean Ϯ S.E. (error bars).
The maximum reactivation efficacy of Br-PBTC relative to maximal ACh responses is 92.5 Ϯ 2.7% for (␣4␤2) 2 ␣4 but only 27.6 Ϯ 6.5% for (␣4␤2) 2 ␤2. These data suggest that Br-PBTC reactivates long term desensitized (␣4␤2) 2 ␣4 nAChRs more efficiently. Thus both activation and reactivation are more efficient with three ACh binding sites. This potentiation of Br-PBTC is specific to agonist-desensitized nAChRs. Br-PBTC could not reactivate antagonist-inactivated nAChRs (green traces in Fig. 9 ).
Competitive Antagonists Block Potentiation by Br-PBTC-Competitive antagonists block activation by agonists because they bind to the same sites as agonists but do not activate nAChRs. We investigated whether competitive antagonists affect potentiation of the allosteric ligand Br-BPTC. One of the important native nAChR subtypes that contain only one potential Br-PBTC site is (␣6␤2)(␣4␤2)␤3 (33) . This is the subtype that regulates nicotine addiction because knock-out of ␣4, ␣6, or ␤2 abolished nicotine self-administration in rodents (34) . Br-PBTC did not potentiate activation of (␣6␤2) 2 ␤3 expressed in oocytes (data not shown), but it increased ACh (3 M) activation of (␣6␤2)(␣4␤2)␤3 by 99.0 Ϯ 13.6% (representative kinetics shown in Fig. 10A ). This is consistent with the finding in Fig. 5 that only one ␣4 subunit is required for Br-PBTC potentiation. One feature of (␣6␤2)(␣4␤2)␤3 is that the competitive antagonist ␣-conotoxin MII selectively blocks its activation from the ␣6/␤2 interface. This antagonist site is far away from the ␣4 C-tail where Br-PBTC acts. ␣-Conotoxin MII (50 nM) completely blocked activation by ACh and potentiation by Br-PBTC (Fig. 10B ). This is consistent with the idea that activation is a cooperative event involving conformational change in the whole nAChR, and antagonist inhibition of any one ACh site is sufficient to prevent activation (35, 36) . Blockage by competitive antagonists also applies to potentiation of Br-PBTC on other ␣4* nAChRs. The competitive antagonist DH␤E selective for ␤2 nAChRs blocked activation of HEK cell lines expressing (␣4␤2) 2 ␤2 and (␣4␤2) 2 ␣4 nAChRs in the presence of Br-PBTC ( Fig. 11 ). DH␤E also inhibited reactivation of both short term and long term desensitized nAChRs by Br-PBTC (gray traces in Figs. 8 and 9 ).
Discussion
Developing subtype-selective therapeutics is challenging for nAChRs. Efforts have been made to develop allosteric modulators binding to non-conserved regions to achieve subtype selectivity (6, 7) . Only the human ␣2 and ␣4 subunits share similar sequences at the C-tail. Other human subunits differ in length and the amino acid sequences in this region. This makes the C-tail a promising target for selective PAMs. Here we showed that, besides steroids, non-steroid structures could act from the ␣4 C-tail as PAMs and exhibit submicromolar affinity. Engineering the ␣4 C-tail onto ␤2 subunits enabled estrogens to potentiate through this mutant ␤2 subunit (15) . A suitable PAM to bind the C-tail of ␤2 and interact with the end of its M4 might produce a ␤2-selective effect. Perhaps in this way PAMs could be found that would be selective for any subunit. These ligands might behave similarly to type II PAMs like Br-PBTC, but they might also be negative allosteric modulators or allosteric agonists, depending on their structures. There is not clear guidance for how to design or select such ligands, but 17␤estradiol and Br-PBTC illustrate examples of structurally different compounds with similar PAM properties. Suitable selection approaches using stoichiometry-specific nAChR cell lines might allow for the discovery of PAMs, negative allosteric modulators, and allosteric agonists for many nAChR subunits that would be useful tools for studying nAChRs and as drugs both in vitro and in vivo.
The C-tail PAM site is stereoselective. Neither the enantiomer of Br-PBTC 5 nor estrogens (14) potentiate ␣4* nAChRs. Stereoselectivity suggests that the PAM and the C-tail of the ␣4 subunit interact with protein rather than membrane lipid. PAM bound to the short ␣4 C-tail must interact stereospecifically with a nearby region, probably on the same subunit, which is capable of influencing the channel gate. There are prolines at the extracellular end of the M4 transmembrane domains. These prolines may contribute to a stereoselective site that interacts with the PAM bound to the C-tail to mediate the PAM effects. Several other important subunit structural elements are close to this stereoselective site: the end of ␤10 strand to M1, the cys-loop, M2-M3 loop, ␤1-␤2 loop, and ␤8-␤9 loop. Movement of these structural elements contributes to passing the conformational changes from binding of the agonist in the extracellu-lar domain to opening of the transmembrane channel pore (37, 38) . Ivermectin, a compound acting directly on these structural elements, is a PAM on ␣7 (6) and an allosteric agonist on glutamate-gated chloride channels where its binding site has been localized in receptor crystals near this region (38) . A lipid molecule binds competitively to the same region as ivermectin (39) . Both ivermectin and this lipid induce channel pore opening but through slightly different conformation changes. These suggest that the transmembrane domains are quite flexible. The subtleties involved in channel opening are small (39); thus, pulling or pushing a bit on the extracellular end of M4 might be enough to mediate action of a PAM.
Although Br-PBTC acts from ␣ subunits, ␤ subunits also play a role. Br-PBTC has greater effects on nAChRs with ␤2 subunits over those with ␤4 subunits (Fig. 2) . It is not clear whether this is because of the greater sensitivity to activation of ␤2* nAChRs or because ␤ subunits directly contribute to the Br-PBTC PAM effect.
It is not evident how a PAM binding to an ␣4 C-tail affects activation or desensitization. Estrogens do not potentiate ␣4 subunits whose C-terminal end is linked into another subunit such as the concatemer ␣4-␤2 (29) . However, Br-PBTC potentiated the C-tail-linked ␣4 subunit equally efficiently as the free subunit ( Figs. 5 and 6 ). This allowed us to express various concatemers with a free ␣3 subunit to reduce binding sites for Br-PBTC ( Fig. 6) . We cannot rule out the possibility that Br-BPTC can bind to the ␣3 C-tail but cannot potentiate nAChR activation. Occupancy by agonists affects nAChR activation and desensitization (11, 12) . Using an ␣3 subunit to replace ␣4 maintained the number of agonist sites among nAChRs. Therefore, Br-PBTC is a better tool than estrogens to study the relationship between occupancy and potentiation of PAMs acting at the C-tail. Moreover, given the activity of estrogens at nuclear receptors, Br-PBTC would be a better ligand to study effects of nAChRs in vivo. That Br-PBTC potentiated linked ␣4 C-tails in concatemers indicates that a free tip of the C-tail is not required for potentiation from this site. The linker in the ␣4-␤2 concatemer might have prevented the entrance of estrogens into the C-tail site.
A previous study used concatemers to achieve different numbers of ␣4 subunits with free C-tails and showed that more ␣4 subunits increased potentiation efficacy by estrogens (15) . Using Br-PBTC, we confirmed and extended this C-tail potentiation mechanism. Upon agonist binding, nAChRs go through various conformational changes from the resting state (R) to the open state (O) and or desensitized state (D) (Fig. 12A ). There are different types of desensitized states (6, 40, 41) . Some have lower energy barriers and are favored soon after ligand binding, i.e. short term desensitization (D S ). Some have lower energy levels and are preferred after long term incubation with agonists (D L ). When an antagonist binds, nAChRs go into an inactive state (I) or are forced to remain in a resting state that prevents activation. When a PAM binds to the C-tail of ␣4, it increases the probability of channel opening (42) . The increase of channel open probability only requires one C-tail site, and its extent is proportionate to the number of C-tail PAM sites in a nAChR (Figs. 6B and 12B) (15) . PAMs reactivate short term desensitized nAChRs from the C-tail also in an occupancy-de- pendent manner but require occupying two or more C-tail sites (Figs. 7) . This suggests that Br-PBTC increases exit rates from the D S state to the O state, thus destabilizing the D S state (Fig.   12B ). Occupying three C-tail sites is required to efficiently reactivate long term desensitized nAChRs ( Figs. 9 and 11B ). The D L state is favored over time because it has the lowest energy level. Br-PBTC likely needs to bind to three ␣4 subunits to initiate sufficient conformational change to compensate for the energy loss from leaving the D L state. The cooperative effect of Br-PBTC binding to three sites also enables Br-PBTC to increase agonist sensitivity of (␣4␤2) 2 ␣4 nAChRs. PAMs at the ␣4 C-tail cannot activate antagonist-bound nAChRs, and antagonists block their potentiation ( Figs. 8 -11 ). This is consistent with the concerted conformational change model for activation, i.e. any one ACh site being held in a resting conformation through an antagonist blocking closing of its C-loop prevents activation (43) .
␣4␤2* nAChRs are the most prevalent subtypes in brain (44) . PAMs promoting activation of these nAChRs could be beneficial in improving cognition, movement, learning, and memory and reducing pain or aggressive behaviors, thus beneficial for analgesia, autism, Parkinson, or Alzheimer diseases (2, 3, 7, 45, 46) . ␣4␤2* PAMs are also promising in treating nicotine addiction. Sustained levels of nicotine, which usually keep high affinity nAChRs desensitized, are found in chronic smokers (32) . An ␣4␤2 type II PAM, desformylflustrabromine (dFBr), reduced nicotine self-administration in rats (47) . dFBr potentiates nAChR functions through binding to the principal face of ␤2 subunits homologous to the ACh site at the principal face of ␣ subunits (48) . This is similar to how morantel potentiates ␣3␤2 nAChRs (49) but different from Br-PBTC. Although differing in binding, Br-PBTC may also benefit smokers like desformylflustrabromine because potentiation of (␣6␤2)(␣4␤2)␤3 nAChRs might achieve sufficient reward from lower concentrations of nicotine (34) and because potentiation of (␣4␤2) 2 ␣5 nAChRs might increase aversion to high concentrations of nicotine (50) .
The unique potentiation profile of Br-PBTC makes it a good research tool for differentiating nAChR subtypes. The nAChR subtype expression pattern differs between brain areas (5, 33) . The ␣6-selective antagonist ␣-conotoxin MII helps distinguish ␣6 and non-␣6 nAChRs. Br-PBTC selectively potentiates ␣6␣4* nAChRs. This differentiates them from ␣6(non␣4) nAChRs. In combination with ␣-conotoxin MII, Br-PBTC can further distinguish ␣4␣6* from ␣4(non␣6) nAChRs. Because Therefore, a question mark for agonist binding is annotated at those undefined interfaces. Higher PAM occupancy increases the probability of nAChRs being in the open state and decreases the probability in the D S or D L states. Therefore, ␣4-selective PAMs showed the greatest potentiation effect on (␣4␤2) 2 ␣4 nAChRs with three ␣4 subunits.
Br-PBTC selectively reactivates long term desensitized (␣4␤2) 2 ␣4 nAChRs, it can be used in vivo to distinguish this subtype from other nAChR subtypes, such as (␣4␤2) 2 ␣5, (␣4␤2) 2 ␤2, (␣4␤2) 2 ␤3 etc.
In summary, using the novel type II PAM Br-PBTC, we learned more about potentiation from the C-tail PAM site. We found that activation and reactivation increase with higher PAM occupancy at the C-tail site. It remains to be determined in vivo how chronic exposure to ACh or agonist drugs in the presence of Br-PBTC will influence smoldering activation of nAChRs largely desensitized by agonists. It also remains to be determined how ligands bound to the ␣4 C-tail interact with the channel to influence its opening, whether negative allosteric modulators or allosteric agonists can act from this site, whether similar sites can be found on other subunits, and whether ligands for them will prove to be useful drugs.
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